Log In
BCIQ
Print this Print this
 

Anti-C5aR-215 (NN8210)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionRecombinant mAb
Molecular Target Complement 5a (C5a)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today